Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip
Public ClinicalTrials.gov record NCT02683239. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Double-blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Long-Term Safety and the Efficacy of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to describe the safety and tolerability of fasinumab, including adverse events of special interest (AESIs), in patients with pain due to radiographically-confirmed OA of the knee or hip.
Study identification
- NCT ID
- NCT02683239
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 5,331 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 17, 2016 (Actual)
- Primary completion
- Dec 1, 2020 (Actual)
- Completion
- Jun 15, 2021 (Actual)
- Last update posted
- Oct 13, 2023
2016 – 2021
United States locations
- U.S. sites
- 50
- U.S. states
- 22
- U.S. cities
- 47
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Regeneron Investigational Site | Birmingham | Alabama | 35211 | — |
| Regeneron Investigational Site #1 | Chandler | Arizona | 85224 | — |
| Regeneron Investigational Site #2 | Chandler | Arizona | 85224 | — |
| Regeneron Investigational Site | Glendale | Arizona | 85308 | — |
| Regeneron Investigational Site | Mesa | Arizona | 85213 | — |
| Regeneron Investigational Site (4 locations) | Phoenix | Arizona | 85018 | — |
| Regeneron Investigational Site | Tempe | Arizona | 85224 | — |
| Regeneron Investigational Site (2 locations) | Tucson | Arizona | 85712 | — |
| Regeneron Investigational Site | Little Rock | Arkansas | 72205 | — |
| Regeneron Investigational Site | Beverly Hills | California | 90211 | — |
| Regeneron Investigational Site | Carlsbad | California | 92008 | — |
| Regeneron Investigational Site | San Diego | California | 92103 | — |
| Regeneron Investigational Site | San Marcos | California | 92078 | — |
| Regeneron Investigational Site | Vista | California | 92083 | — |
| Regeneron Investigational Site | Aurora | Colorado | 80014 | — |
| Regeneron Investigational Site | Colorado Springs | Colorado | 80909 | — |
| Regeneron Investigational Site | Golden | Colorado | 80401 | — |
| Regeneron Investigational Site | Littleton | Colorado | 80127 | — |
| Regeneron Investigational Site | Clearwater | Florida | 33765 | — |
| Regeneron Investigational Site | Orlando | Florida | 32801 | — |
| Regeneron Investigational Site | Pinellas Park | Florida | 33781 | — |
| Regeneron Investigational Site | Atlanta | Georgia | 30328 | — |
| Regeneron Investigational Site (3 locations) | Chicago | Illinois | 60602 | — |
| Regeneron Investigational Site | Evansville | Illinois | 47714 | — |
| Regeneron Investigational Site | Kansas City | Kansas | 64114 | — |
| Regeneron Investigational Site | Frederick | Maryland | 21702 | — |
| Regeneron Investigational Site | Worcester | Massachusetts | 01605 | — |
| Regeneron Investigational Site | Richfield | Minnesota | 55423 | — |
| Regeneron Investigational Site #1 | St Louis | Missouri | 63141 | — |
| Regeneron Investigational Site #2 | St Louis | Missouri | 63141 | — |
| Regeneron Investigational Site | Elkhorn | Nebraska | 68022 | — |
| Regeneron Investigational Site | Fremont | Nebraska | 68025 | — |
| Regeneron Investigational Site | Omaha | Nebraska | 68144 | — |
| Regeneron Investigational Site | Las Vegas | Nevada | 89128 | — |
| Regeneron Investigational Site | Jamaica | New York | 11432 | — |
| Regeneron Investigational Site | New York | New York | 10036 | — |
| Regeneron Investigational Site | High Point | North Carolina | 27262 | — |
| Regeneron Investigational Site | Akron | Ohio | 44311 | — |
| Regeneron Investigational Site | Cincinnati | Ohio | 45219 | — |
| Regeneron Investigational Site | Columbus | Ohio | 43212 | — |
| Regeneron Investigational Site | Oklahoma City | Oklahoma | 73119 | — |
| Regeneron Investigational Site | Duncansville | Pennsylvania | 16635 | — |
| Regeneron Investigational Site | Anderson | South Carolina | 29621 | — |
| Regeneron Investigational Site | Greer | South Carolina | 29651 | — |
| Regeneron Investigational Site #1 | Dallas | Texas | 75234 | — |
| Regeneron Investigational Site #2 | Dallas | Texas | 75234 | — |
| Regeneron Investigational Site | Houston | Texas | 77008 | — |
| Regeneron Investigational Site | Lubbock | Texas | 79424 | — |
| Regeneron Investigational Site | Plano | Texas | 75093 | — |
| Regeneron Investigational Site | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 99 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02683239, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 13, 2023 · Synced Oct 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02683239 live on ClinicalTrials.gov.